- Home
- BCAL vs MDXG Comparison
BCAL vs MDXG Comparison
Compare BCAL & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAL | MDXG |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.9M | 530.2M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BCAL | MDXG |
|---|---|---|
| Price | $19.62 | $3.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $20.67 | $9.00 |
| AVG Volume (30 Days) | 160.2K | ★ 1.2M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 777.27 | 14.29 |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.67 | $13.02 |
| P/E Ratio | $47.00 | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $14.57 | $3.03 |
| 52 Week High | $20.47 | $7.99 |
Technical Indicators
Market Signals| Indicator | BCAL | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 51.85 |
| Support Level | $18.49 | $3.50 |
| Resistance Level | $19.95 | $3.84 |
| Average True Range (ATR) | 0.41 | 0.13 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 75.74 | 50.00 |
Price Performance
Historical ComparisonAbout BCAL Southern California Bancorp
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.